VLS — Vita Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- AU$144.29m
- AU$111.03m
- AU$93.27m
Annual cashflow statement for Vita Life Sciences, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.141 | 0.131 | 0.558 | 1.04 | 0.991 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 5.89 | 2.77 | 13 | 6.16 | 16.4 |
| Capital Expenditures | -0.155 | -0.139 | -0.66 | -0.198 | -0.57 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.155 | -0.139 | -0.66 | -0.198 | -0.57 |
| Financing Cash Flow Items | — | 0.582 | 0.871 | 3.86 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.39 | -3.1 | -2.88 | -2.99 | -9.09 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.42 | -0.205 | 8.94 | 3.97 | 6.96 |